1.Too Low From a Self-Blow: Diagnostic and Therapeutic Challenges in a Case of Hirata’s Syndrome
Tharsini Sarvanandan ; Ying Guat Ooi ; Jun Kit Khoo ; Tricia Lopez ; Nicholas Ken Yoong Hee ; Shireene Vethakkan ; Lee-Ling Lim ; Jeyakantha Ratnasingam ; Carolyn Chee ; Pavai Sthaneshwar ; Quan Hziung Lim
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):50-
Introduction:
Non-diabetic hypoglycemia in older adults warrants
careful evaluation across insulin-mediated and noninsulin-mediated causes. We present a challenging case of
insulin autoimmune syndrome (IAS; Hirata’s syndrome).
Case:
An 85-year-old female presented with severe hypoglycemia (capillary blood glucose [CBG] 1.8 mmol/L) with
reduced consciousness, preceded by 2 months of recurrent
dizziness relieved by food intake. Appetite and weight were
stable. Past medical history included stage 3 chronic kidney
disease and osteoporosis, but no diabetes. Medication
review revealed a recent 2-week course of traditional
supplement, long-term Neurobion®, but no agents with
recognized hypoglycemic potential. Physical examination
showed a moderately built elderly female with a body
mass index of 24.3 kg/m² and no Cushingoid features.
Recurrent hypoglycemia (CBG nadir 1.5 mmol/L) occurred
in both fasting and postprandial states, fulfilling Whipple’s
triad. Baseline investigations showed an estimated
glomerular filtration rate of 42 mL/min/1.73 m², AM
cortisol of 700 mmol/L, and unremarkable liver and thyroid
function tests. During a hypoglycemic episode (CBG 2.3
mmol/L), plasma insulin and C-peptide were inappropriately raised at 203.6 mU/L (reference interval [RI]: 3.0–
25.0) and 33 ng/mL (RI: 0.9–7.1), respectively, confirming
endogenous hyperinsulinemic hypoglycemia. Polyethylene
glycol precipitation showed 21% insulin recovery, raising
suspicion for an autoimmune cause. Elevated insulin
autoantibodies (175 AU/mL; RI <20) confirmed IAS.
Computed tomography of the abdomen and endoscopic
ultrasound excluded a pancreatic neuro-endocrine tumor.
Nutritional management comprising frequent low glycemic
index feeds and uncooked cornstarch was commenced.
Diazoxide 100 mg TDS caused fluid overload and severe
hyponatremia, while hypoglycemia persisted at lower doses, necessitating discontinuation. Subcutaneous octreotide 100 mg QID was required to control hypoglycemia.
Prednisolone 30 mg BD improved glycemic stability. Insulin
autoantibodies titer remained 175 AU/mL at 2 weeks;
reassessment was conducted at 4 weeks with consideration for biologics if persistent.
:
doses, necessitating discontinuation. Subcutaneous octreotide 100 mg QID was required to control hypoglycemia.
Prednisolone 30 mg BD improved glycemic stability. Insulin
autoantibodies titer remained 175 AU/mL at 2 weeks;
reassessment was conducted at 4 weeks with consideration for biologics if persistent.
Conclusion
Endogenous hyperinsulinemic hypoglycemia, after
excluding insulinoma, should raise suspicion for IAS.
Management includes removing triggers, supportive care,
and immunomodulatory therapy in severe cases.
2.Cold Spot Within a Hot Nodule: Thyroid Storm from Toxic Adenoma Revealing Rare Hurthle Cell Adenoma
Ying Guat Ooi ; Jun Kit Khoo ; Tharsini Sarvanandan ; Quan Hziung Lim ; Jeyakantha Ratnasingam ; Lee Ling Lim ; Shireene Ratna Vethakkan ; Nicholas Ken Yoong Hee
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):103-104
Introduction:
Hurthle cell adenoma is a rare benign thyroid neoplasm
that can only be diagnosed through histopathological
examination. Hurthle cell neoplasm typically presents as
nonfunctioning cold nodule on thyroid scintigraphy. We
report a rare case of Hurthle cell adenoma presenting with
thyroid storm, with unusual findings of “cold” within
“hot” thyroid nodule on scintigraphy.
Case:
A 73-year-old male with hypertension, chronic kidney
disease, coronary artery disease, and Parkinson’s disease
presented to the emergency department with fever and
diarrhea. His temperature was 38.4°C, heart rate 106 bpm,
and blood pressure 138/75 mmHg, with atrial fibrillation
and signs of heart failure. The Burch-Wartofsky score was
50, consistent with thyroid storm.
Laboratory tests revealed free thyroxine 4 37.8 pmol/L
(NR 11.5–22.7), free thyroxine 3 5.6 pmol/L (NR 3.5–6.5),
and thyroid-stimulating hormone <0.01 mIU/L (NR 0.55–
4.78). Thyroid autoantibodies, including anti-thyroid
peroxidase, anti-thyroglobulin, and thyroid-stimulating
immunoglobulins, were negative (<0.10 IU/L). The thyroid
storm was precipitated by invasive Klebsiella syndrome
with endophthalmitis and lung and liver abscess. He was
treated with Lugol’s iodine, corticosteroid, antibiotics, and
carbimazole.
Ultrasound thyroid revealed a mixed cystic-solid nodule
in the left thyroid lobe, measuring 2.3 × 3.3 × 4.3 cm (TIRADS category 3). Technetium-99m thyroid scintigraphy
demonstrated a hyperfunctioning left thyroid nodule with
a focal intranodular cold spot measuring 5.0 × 3.7 cm.
Fine needle aspiration cytology of the nodule was benign
follicular cells. Following stabilization with anti-thyroid
treatment, he underwent left hemithyroidectomy. Histopathology examination revealed a Hurthle cell adenoma
without capsular or vascular invasion.
Postoperatively, he remained clinically euthyroid. Surveillance ultrasound performed 8 months later showed a
normal right thyroid lobe, and lifelong surveillance was
planned.
Conclusion
This case illustrates a rare and unusual presentation of
thyroid storm caused by a toxic Hurthle cell adenoma
containing an intranodular cold spot on scintigraphy. To
our knowledge, only one similar case has been reported
in the literature, and our case is the first to present with
thyroid storm.
Oxyphil Cells
;
Thyroid Crisis
;
Adenoma
3.From Stability to Storm: Thyroid Storm After a Decade of Antithyroid Drug
Jun Kit Khoo ; Tharsini Sarvanandan ; Ying Guat Ooi ; Quan Hziung Lim ; Carolyn Wai Ling Chee ; Lee Ling Lim ; Jeyakantha Ratnasingam ; Shireene Ratna Vethakkan ; Nicholas Ken Yoong Hee
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):111-
Introduction:
Long-term antithyroid drug (LT-ATD) has emerged as
a feasible treatment strategy for patients who decline
radioactive iodine (RAI) or thyroidectomy for relapsed
or refractory Graves’ disease (GD). Benefits include
faster achievement of euthyroidism, lower risk of hypothyroidism, a more favorable cardiovascular profile, and
avoidance of surgical risks. Although fluctuations in
thyroid status may occur despite good compliance, thyroid
storm is exceedingly rare in patients on LT-ATD. While
there is no specific data on the incidence of thyroid storm
in this cohort, surveys suggest an overall low incidence
(0.2–0.76 cases per 100,000 annually). We report a patient
with stable GD who developed a thyroid storm despite
more than 10 years of LT-ATD.
Case:
A 40-year-old female was diagnosed with GD 11 years
earlier during pregnancy. Treatment was stopped at 25
weeks’ gestation, but she relapsed at 7 months postpartum
and was started on carbimazole. She declined RAI or
surgery following a relapse and remained on carbimazole
5–10 mg daily, with good compliance. She presented with
a 1-day history of fever, cough, rhinorrhea, diarrhea, and
palpitations. She was compliant with carbimazole 5 mg
daily. On presentation, BP was 132/70 mmHg, HR 140
bpm, temperature 38.5°C, and SpO2 98% on air. She was
alert without agitation, had a diffuse goiter, mild proptosis,
and conjunctival injection, with otherwise normal
findings. Electrocardiogram showed sinus tachycardia.
Laboratory investigations demonstrated mild transaminitis,
leukocytosis, markedly elevated free T4 (>154 pmol/L),
suppressed thyroid-stimulating hormone (<0.008 mIU/L),
and elevated thyroid-stimulating immunoglobulin (2.25 IU/L, reference <0.55). Thyroid function tests 1 month ago
was normal. Her Burch-Wartofsky score was 60, consistent
with thyroid storm, likely precipitated by upper respiratory
tract infection. She improved with treatment and was
discharged with carbimazole 30 mg daily with planned
tapering, subsequently agreeing to RAI as definitive
treatment.
Conclusion
Infection may trigger thyroid storm despite good
compliance with LT-ATD. Patients should be counselled
regarding this risk and advised to seek early medical
attention if thyrotoxic symptoms recur.
Antithyroid Agents
;
Thyroid Crisis
4.Expert Consensus on the Ethical Requirements for Generative AI-Assisted Academic Writing
You-Quan BU ; Yong-Fu CAO ; Zeng-Yi CHANG ; Hong-Yu CHEN ; Xiao-Wei CHEN ; Yuan-Yuan CHEN ; Zhu-Cheng CHEN ; Rui DENG ; Jie DING ; Zhong-Kai FAN ; Guo-Quan GAO ; Xu GAO ; Lan HU ; Xiao-Qing HU ; Hong-Ti JIA ; Ying KONG ; En-Min LI ; Ling LI ; Yu-Hua LI ; Jun-Rong LIU ; Zhi-Qiang LIU ; Ya-Ping LUO ; Xue-Mei LV ; Yan-Xi PEI ; Xiao-Zhong PENG ; Qi-Qun TANG ; You WAN ; Yong WANG ; Ming-Xu WANG ; Xian WANG ; Guang-Kuan XIE ; Jun XIE ; Xiao-Hua YAN ; Mei YIN ; Zhong-Shan YU ; Chun-Yan ZHOU ; Rui-Fang ZHU
Chinese Journal of Biochemistry and Molecular Biology 2025;41(6):826-832
With the rapid development of generative artificial intelligence(GAI)technologies,their widespread application in academic research and writing is continuously expanding the boundaries of sci-entific inquiry.However,this trend has also raised a series of ethical and regulatory challenges,inclu-ding issues related to authorship,content authenticity,citation accuracy,and accountability.In light of the growing involvement of AI in generating academic content,establishing an open,controllable,and trustworthy ethical governance framework has become a key task for safeguarding research integrity and maintaining trust within the academic community.This expert consensus outlines ethical requirements across key stages of AI-assisted academic writing-including topic selection,data management,citation practices,and authorship attribution.It aims to clarify the boundaries and ethical obligations surrounding AI use in academic writing,ensuring that technological tools enhance efficiency without compromising in-tegrity.The goal is to provide guidance and institutional support for building a responsible and sustainable research ecosystem.
5.Forty years of construction and innovative development of scientific regulation system of traditional Chinese medicine in China.
Jun-Ning ZHAO ; Zhi-Shu TANG ; Hua HUA ; Rong SHAO ; Jiang-Yong YU ; Chang-Ming YANG ; Shuang-Fei CAI ; Quan-Mei SUN ; Dong-Ying LI
China Journal of Chinese Materia Medica 2025;50(13):3489-3505
Since the promulgation of the first Drug Administration Law of the People's Republic of China 40 years ago in 1984, China has undergone four main stages in the traditional Chinese medicine(TCM) regulation: the initial establishment of TCM regulation rules(1984-1997), the formation of a modern TCM regulatory system(1998-2014), the reform of the review and approval system for new TCM drugs(2015-2018), and the construction of a scientific regulation system for TCM(2019-2024). Over the past five years, a series of milestone achievements of TCM regulation in China have been achieved in the six aspects, including its strategic objectives and the establishment of a science-based regulatory system, the reform of the review and approval system for new TCM drugs, the optimization and improvement of the TCM standard system and its formation mechanism, comprehensive enhancement of regulatory capabilities for TCM safety, international harmonization of TCM regulation and its role in promoting innovation. Looking ahead, centered on advancing TCMRS to establish a sound regulatory framework tailored to the unique characteristics of TCM, TCM regulation will evolve into new reform patterns, advancing and extending across eight critical fronts, including the legal framework and policy architecture, the review and approval system for new TCM drugs, the quality standard and management system of TCM, the comprehensive quality & safety regulation and traceability system, the research and transformation system for TCMRS, AI-driven innovations in TCM regulation, the coordination between high-quality industrial development and high-level regulation, and the leadership in international cooperation and regulatory harmonization. In this way, a unique path for the development of modern TCM regulation with Chinese characteristics will be pioneered.
Humans
;
China
;
Drugs, Chinese Herbal/standards*
;
History, 20th Century
;
History, 21st Century
;
Medicine, Chinese Traditional/trends*
6.Mechanism of SOS1-IT1 promoting EZH2 expression in human endometrial cancer cells by regulating acetylation modification
Hong-Yang LIU ; Xue-Ling LOU ; Rong-Jing ZHANG ; Quan-Ling FENG ; Kai-Ge GUO ; Hao-Fan WANG ; Ying-Ying LI ; Jun-Hu WAN ; Lin-Dong ZHANG
Acta Anatomica Sinica 2025;56(4):444-451
Objective To explore the molecular mechanism by which SOS Ras/Rac guanine nucleotide exchange factor 1-intronic transcript 1(SOS1-IT1)affects enhancer of zeste homolog 2(EZH2)protein expression in endometrial cancer cells Ishikawa and RL95-2.Methods Lentiviral transfection of short hairpin RNA(shRNA)and overexpression plasmid were used in Ishikawa and RL95-2 cell lines to knock down and overexpress SOS1-IT1.The mechanism of EZH2 expression regulation was studied using Real-time PCR,Western blotting,and chromatin immunoprecipitation.Results The expression of SOS1-IT1 and EZH2 genes was positively correlated in endometrial cancer tissues.Knocking down SOS1-IT1 significantly reduces the expression of EZH2,inhibited the proliferation and migration of Ishikawa and RL95-2 cells,and could reduced the acetylation of histone H3 at position 27(H3K27)and the enrichment of CREB binding protein(CBP)in the EZH2 gene promoter region.Overexpression of SOS1-IT1 could increased the expression of EZH2 and enhance the acetylation of H3K27 and the enrichment of CBP.CBP could bind to SOS1-IT1 RNA,and this binding ability was weakened when CBP was knocked down.Conclusion SOS1-IT1 can promote the expression level of EZH2 in endometrial cancer cells Ishikawa and RL95-2 by regulating the acetylation modification level of the EZH2 gene promoter region,thereby affecting the proliferation and migration ability of endometrial cancer cells.
7.Expert Consensus on the Ethical Requirements for Generative AI-Assisted Academic Writing
You-Quan BU ; Yong-Fu CAO ; Zeng-Yi CHANG ; Hong-Yu CHEN ; Xiao-Wei CHEN ; Yuan-Yuan CHEN ; Zhu-Cheng CHEN ; Rui DENG ; Jie DING ; Zhong-Kai FAN ; Guo-Quan GAO ; Xu GAO ; Lan HU ; Xiao-Qing HU ; Hong-Ti JIA ; Ying KONG ; En-Min LI ; Ling LI ; Yu-Hua LI ; Jun-Rong LIU ; Zhi-Qiang LIU ; Ya-Ping LUO ; Xue-Mei LV ; Yan-Xi PEI ; Xiao-Zhong PENG ; Qi-Qun TANG ; You WAN ; Yong WANG ; Ming-Xu WANG ; Xian WANG ; Guang-Kuan XIE ; Jun XIE ; Xiao-Hua YAN ; Mei YIN ; Zhong-Shan YU ; Chun-Yan ZHOU ; Rui-Fang ZHU
Chinese Journal of Biochemistry and Molecular Biology 2025;41(6):826-832
With the rapid development of generative artificial intelligence(GAI)technologies,their widespread application in academic research and writing is continuously expanding the boundaries of sci-entific inquiry.However,this trend has also raised a series of ethical and regulatory challenges,inclu-ding issues related to authorship,content authenticity,citation accuracy,and accountability.In light of the growing involvement of AI in generating academic content,establishing an open,controllable,and trustworthy ethical governance framework has become a key task for safeguarding research integrity and maintaining trust within the academic community.This expert consensus outlines ethical requirements across key stages of AI-assisted academic writing-including topic selection,data management,citation practices,and authorship attribution.It aims to clarify the boundaries and ethical obligations surrounding AI use in academic writing,ensuring that technological tools enhance efficiency without compromising in-tegrity.The goal is to provide guidance and institutional support for building a responsible and sustainable research ecosystem.
8.Plasma club cell secretory protein reflects early lung injury: comprehensive epidemiological evidence.
Jiajun WEI ; Jinyu WU ; Hongyue KONG ; Liuquan JIANG ; Yong WANG ; Ying GUO ; Quan FENG ; Jisheng NIE ; Yiwei SHI ; Xinri ZHANG ; Xiaomei KONG ; Xiao YU ; Gaisheng LIU ; Fan YANG ; Jun DONG ; Jin YANG
Environmental Health and Preventive Medicine 2025;30():26-26
BACKGROUND:
It is inaccurate to reflect the level of dust exposure through working years. Furthermore, identifying a predictive indicator for lung function decline is significant for coal miners. The study aimed to explored whether club cell secretory protein (CC16) levels can reflect early lung function changes.
METHODS:
The cumulative respiratory dust exposure (CDE) levels of 1,461 coal miners were retrospectively assessed by constructed a job-exposure matrix to replace working years. Important factors affecting lung function and CC16 were selected by establishing random forest models. Subsequently, the potential of CC16 to reflect lung injury was explored from multiple perspectives. First, restricted cubic spline (RCS) models were used to compare the trends of changes in lung function indicators and plasma CC16 levels after dust exposure. Then mediating analysis was performed to investigate the role of CC16 in the association between dust exposure and lung function decline. Finally, the association between baseline CC16 levels and follow-up lung function was explored.
RESULTS:
The median CDE were 35.13 mg/m3-years. RCS models revealed a rapid decline in forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and their percentages of predicted values when CDE exceeded 25 mg/m3-years. The dust exposure level (<5 mg/m3-years) causing significant changes in CC16 was much lower than the level (25 mg/m3-years) that caused changes in lung function indicators. CC16 mediated 11.1% to 26.0% of dust-related lung function decline. Additionally, workers with low baseline CC16 levels experienced greater reductions in lung function in the future.
CONCLUSIONS
CC16 levels are more sensitive than lung indicators in reflecting early lung function injury and plays mediating role in lung function decline induced by dust exposure. Low baseline CC16 levels predict poor future lung function.
Uteroglobin/blood*
;
Humans
;
Dust/analysis*
;
Occupational Exposure/analysis*
;
Male
;
Middle Aged
;
Adult
;
Retrospective Studies
;
Lung Injury/chemically induced*
;
Coal Mining
;
Biomarkers/blood*
;
China/epidemiology*
;
Air Pollutants, Occupational
;
Female
9.Liuwei Dihuang Pills-elicited inhibition of MMP-2/MMP-9 via RAGE on tight junction protein of Aβ1-40-injured bEnd.3 cells
Rui DING ; Yong YUAN ; Ya-Quan JIA ; Ai-She GAO ; Zhen-Qiang ZHANG ; Jun-Ying SONG
Chinese Traditional Patent Medicine 2024;46(2):424-430
AIM To investigate the protective effects and the mechanism of the Liuwei Dihuang Pills on mouse brain microvascular endothelial(bEnd.3)cells damaged by β-Amyloid protein1-40(Aβ1-40).METHODS CCK8 method was used to detect the effects of Aβ1-40 and medicated serum of Liuwei Dihuang Pills(MSLDP)on cell activity,and to screen the appropriate concentration.bEnd.3 cells of the control group,the Aβ1-40 group,the MSLDP+Aβ1-40 group and the MSLDP group had their low density lipoprotein-associated protein 1(LRP1),receptor for advanced glycation end products(RAGE),matrix metalloproteinase-2(MMP-2),MMP-9,scaffold protein zonule protein-1(ZO-1)detected by Western blot.bEnd.3 cells assigned into the control group,the Aβ1-40 group,the FPS-ZM1(RAGE inhibitor)+Aβ1-40 group and the FPS-ZM1+Aβ1-40+MSLDP group had their expressions of RAGE,MMP-9,MMP-2 and ZO-1 detected by Western blot as well.RESULTS The cell activity of bEnd.3,was dose-dependently decreased by Aβ1-40(P<0.01),but was protected by MSLDP(P<0.05,P<0.01).And 10 μmol/L Aβ1-40 and 10%MSLDP were selected for subsequent experiments.Compared with the control group,the Aβ1-40 group displayed increased protein expressions of RAGE,MMP-2 and MMP-9(P<0.01),decreased protein expressions of LRP1,ZO-1 and BDNF(P<0.05,P<0.01),and decreased fluorescence intensities of LRP1 and ZO-1(P<0.01).Compared with the Aβ1-40 group,the MSLDP group shared decreased expressions of RAGE,MMP-2,MMP-9 proteins and RAGE fluorescence intensity(P<0.05,P<0.01),and increased expressions of LRP1,ZO-1 and BDNF proteins,and the fluorescence intensity of LRP1 and ZO-1(P<0.05,P<0.01);the Aβ1-40+FPS-ZM1 group displayed decreased protein expressions of MMP-2,MMP9 and RAGE(P<0.05,P<0.01),and increased ZO-1 protein expression(P<0.05);and the Aβ1-40+FPS-ZM1+ MSLDP group displayed an even more decreased protein expressions of MMP-2,MMP9 and RAGE(P<0.01),increased ZO-1 protein expression(P<0.01)due to the the combination use of FPS-ZM1 and MSLDP.CONCLUSION Liuwei Dihuang Pills can protect the tight junction of bEnd.3 injured by Aβ1-40 and neurovascular units from Alzheimer's disease by alleviating the dysfunction of the blood-brain barrier via RAGE-mediated MMP-2/MMP-9 pathway inhibition.
10.Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients (version 2024)
Yao LU ; Yang LI ; Leiying ZHANG ; Hao TANG ; Huidan JING ; Yaoli WANG ; Xiangzhi JIA ; Li BA ; Maohong BIAN ; Dan CAI ; Hui CAI ; Xiaohong CAI ; Zhanshan ZHA ; Bingyu CHEN ; Daqing CHEN ; Feng CHEN ; Guoan CHEN ; Haiming CHEN ; Jing CHEN ; Min CHEN ; Qing CHEN ; Shu CHEN ; Xi CHEN ; Jinfeng CHENG ; Xiaoling CHU ; Hongwang CUI ; Xin CUI ; Zhen DA ; Ying DAI ; Surong DENG ; Weiqun DONG ; Weimin FAN ; Ke FENG ; Danhui FU ; Yongshui FU ; Qi FU ; Xuemei FU ; Jia GAN ; Xinyu GAN ; Wei GAO ; Huaizheng GONG ; Rong GUI ; Geng GUO ; Ning HAN ; Yiwen HAO ; Wubing HE ; Qiang HONG ; Ruiqin HOU ; Wei HOU ; Jie HU ; Peiyang HU ; Xi HU ; Xiaoyu HU ; Guangbin HUANG ; Jie HUANG ; Xiangyan HUANG ; Yuanshuai HUANG ; Shouyong HUN ; Xuebing JIANG ; Ping JIN ; Dong LAI ; Aiping LE ; Hongmei LI ; Bijuan LI ; Cuiying LI ; Daihong LI ; Haihong LI ; He LI ; Hui LI ; Jianping LI ; Ning LI ; Xiying LI ; Xiangmin LI ; Xiaofei LI ; Xiaojuan LI ; Zhiqiang LI ; Zhongjun LI ; Zunyan LI ; Huaqin LIANG ; Xiaohua LIANG ; Dongfa LIAO ; Qun LIAO ; Yan LIAO ; Jiajin LIN ; Chunxia LIU ; Fenghua LIU ; Peixian LIU ; Tiemei LIU ; Xiaoxin LIU ; Zhiwei LIU ; Zhongdi LIU ; Hua LU ; Jianfeng LUAN ; Jianjun LUO ; Qun LUO ; Dingfeng LYU ; Qi LYU ; Xianping LYU ; Aijun MA ; Liqiang MA ; Shuxuan MA ; Xainjun MA ; Xiaogang MA ; Xiaoli MA ; Guoqing MAO ; Shijie MU ; Shaolin NIE ; Shujuan OUYANG ; Xilin OUYANG ; Chunqiu PAN ; Jian PAN ; Xiaohua PAN ; Lei PENG ; Tao PENG ; Baohua QIAN ; Shu QIAO ; Li QIN ; Ying REN ; Zhaoqi REN ; Ruiming RONG ; Changshan SU ; Mingwei SUN ; Wenwu SUN ; Zhenwei SUN ; Haiping TANG ; Xiaofeng TANG ; Changjiu TANG ; Cuihua TAO ; Zhibin TIAN ; Juan WANG ; Baoyan WANG ; Chunyan WANG ; Gefei WANG ; Haiyan WANG ; Hongjie WANG ; Peng WANG ; Pengli WANG ; Qiushi WANG ; Xiaoning WANG ; Xinhua WANG ; Xuefeng WANG ; Yong WANG ; Yongjun WANG ; Yuanjie WANG ; Zhihua WANG ; Shaojun WEI ; Yaming WEI ; Jianbo WEN ; Jun WEN ; Jiang WU ; Jufeng WU ; Aijun XIA ; Fei XIA ; Rong XIA ; Jue XIE ; Yanchao XING ; Yan XIONG ; Feng XU ; Yongzhu XU ; Yongan XU ; Yonghe YAN ; Beizhan YAN ; Jiang YANG ; Jiangcun YANG ; Jun YANG ; Xinwen YANG ; Yongyi YANG ; Chunyan YAO ; Mingliang YE ; Changlin YIN ; Ming YIN ; Wen YIN ; Lianling YU ; Shuhong YU ; Zebo YU ; Yigang YU ; Anyong YU ; Hong YUAN ; Yi YUAN ; Chan ZHANG ; Jinjun ZHANG ; Jun ZHANG ; Kai ZHANG ; Leibing ZHANG ; Quan ZHANG ; Rongjiang ZHANG ; Sanming ZHANG ; Shengji ZHANG ; Shuo ZHANG ; Wei ZHANG ; Weidong ZHANG ; Xi ZHANG ; Xingwen ZHANG ; Guixi ZHANG ; Xiaojun ZHANG ; Guoqing ZHAO ; Jianpeng ZHAO ; Shuming ZHAO ; Beibei ZHENG ; Shangen ZHENG ; Huayou ZHOU ; Jicheng ZHOU ; Lihong ZHOU ; Mou ZHOU ; Xiaoyu ZHOU ; Xuelian ZHOU ; Yuan ZHOU ; Zheng ZHOU ; Zuhuang ZHOU ; Haiyan ZHU ; Peiyuan ZHU ; Changju ZHU ; Lili ZHU ; Zhengguo WANG ; Jianxin JIANG ; Deqing WANG ; Jiongcai LAN ; Quanli WANG ; Yang YU ; Lianyang ZHANG ; Aiqing WEN
Chinese Journal of Trauma 2024;40(10):865-881
Patients with severe trauma require an extremely timely treatment and transfusion plays an irreplaceable role in the emergency treatment of such patients. An increasing number of evidence-based medicinal evidences and clinical practices suggest that patients with severe traumatic bleeding benefit from early transfusion of low-titer group O whole blood or hemostatic resuscitation with red blood cells, plasma and platelet of a balanced ratio. However, the current domestic mode of blood supply cannot fully meet the requirements of timely and effective blood transfusion for emergency treatment of patients with severe trauma in clinical practice. In order to solve the key problems in blood supply and blood transfusion strategies for emergency treatment of severe trauma, Branch of Clinical Transfusion Medicine of Chinese Medical Association, Group for Trauma Emergency Care and Multiple Injuries of Trauma Branch of Chinese Medical Association, Young Scholar Group of Disaster Medicine Branch of Chinese Medical Association organized domestic experts of blood transfusion medicine and trauma treatment to jointly formulate Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients ( version 2024). Based on the evidence-based medical evidence and Delphi method of expert consultation and voting, 10 recommendations were put forward from two aspects of blood support mode and transfusion strategies, aiming to provide a reference for transfusion resuscitation in the emergency treatment of severe trauma and further improve the success rate of treatment of patients with severe trauma.


Result Analysis
Print
Save
E-mail